Combination Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in Antineutrophil Cytoplasm Antibody–Associated Vasculitis
Early withdrawal of oral glucocorticoid therapy in patients with severe AAV treated with combination cyclophosphamide and rituximab induction immunosuppression is safe and effective and may reduce morbidity, in particular serious infections.
Authors
- Fiona A. Chapman (ORCID: https://orcid.org/0000-0002-9774-1643)
- Tariq E. Farrah
- Dan Pugh (ORCID: https://orcid.org/0000-0002-2297-2164)
- Robert W. Hunter (ORCID: https://orcid.org/0000-0003-2344-8978)
- Tania Salehi (ORCID: https://orcid.org/0000-0002-1278-168X)
- Gavin Chapman (ORCID: https://orcid.org/0000-0002-3513-723X)
- Neeraj Dhaun (ORCID: https://orcid.org/0000-0001-9128-6603)
Institutions
- Edinburgh Royal Infirmary (GB)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-04-22
- DOI
- https://doi.org/10.1016/j.ekir.2025.04.030
- Citations
- 7
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 10.63
Funders
- Kidney Research UK